LEXICON PHARMACEUTICALS INC (LXRX)
US5288723027 - Common Stock
We assign a fundamental rating of 2 out of 10 to LXRX. LXRX was compared to 588 industry peers in the Biotechnology industry. Both the profitability and financial health of LXRX have multiple concerns. While showing a medium growth rate, LXRX is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year LXRX has reported negative net income.
In the past year LXRX has reported a negative cash flow from operations.
In the past 5 years LXRX reported 4 times negative net income.
In the past 5 years LXRX reported 4 times negative operating cash flow.
1.2 Ratios
LXRX has a worse Return On Assets (-76.51%) than 69.69% of its industry peers.
LXRX has a worse Return On Equity (-188.53%) than 70.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -76.51% | ||
| ROE | -188.53% | ||
| ROIC | N/A |
ROA(3y)-64.37%
ROA(5y)-38.15%
ROE(3y)-117.64%
ROE(5y)-55.86%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
LXRX has a Gross Margin of 93.09%. This is amongst the best in the industry. LXRX outperforms 95.03% of its industry peers.
LXRX's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for LXRX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 93.09% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.31%
GM growth 5Y-0.65%
2. Health
2.1 Basic Checks
LXRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LXRX has been increased compared to 1 year ago.
Compared to 5 years ago, LXRX has more shares outstanding
Compared to 1 year ago, LXRX has a worse debt to assets ratio.
2.2 Solvency
LXRX has an Altman-Z score of -10.74. This is a bad value and indicates that LXRX is not financially healthy and even has some risk of bankruptcy.
LXRX's Altman-Z score of -10.74 is on the low side compared to the rest of the industry. LXRX is outperformed by 77.74% of its industry peers.
A Debt/Equity ratio of 1.07 is on the high side and indicates that LXRX has dependencies on debt financing.
LXRX has a Debt to Equity ratio of 1.07. This is in the lower half of the industry: LXRX underperforms 78.08% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.07 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -10.74 |
ROIC/WACCN/A
WACC9.49%
2.3 Liquidity
A Current Ratio of 5.60 indicates that LXRX has no problem at all paying its short term obligations.
LXRX has a Current ratio of 5.60. This is comparable to the rest of the industry: LXRX outperforms 59.42% of its industry peers.
LXRX has a Quick Ratio of 5.58. This indicates that LXRX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of LXRX (5.58) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.6 | ||
| Quick Ratio | 5.58 |
3. Growth
3.1 Past
The earnings per share for LXRX have decreased strongly by -31.15% in the last year.
The Revenue has grown by 1104.00% in the past year. This is a very strong growth!
Measured over the past years, LXRX shows a very negative growth in Revenue. The Revenue has been decreasing by -54.71% on average per year.
EPS 1Y (TTM)-31.15%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-25%
Revenue 1Y (TTM)1104%
Revenue growth 3Y-63.12%
Revenue growth 5Y-54.71%
Revenue growth Q2QN/A
3.2 Future
LXRX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.25% yearly.
LXRX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 231.45% yearly.
EPS Next Y9.48%
EPS Next 2Y7.83%
EPS Next 3Y15.35%
EPS Next 5Y29.25%
Revenue Next Year1380.76%
Revenue Next 2Y530.51%
Revenue Next 3Y360.72%
Revenue Next 5Y231.45%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
LXRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LXRX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as LXRX's earnings are expected to grow with 15.35% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.83%
EPS Next 3Y15.35%
5. Dividend
5.1 Amount
No dividends for LXRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
LEXICON PHARMACEUTICALS INC
NASDAQ:LXRX (4/24/2024, 3:22:22 PM)
After market: 1.59 -0.01 (-0.62%)1.6
-0.01 (-0.62%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap393.98M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -76.51% | ||
| ROE | -188.53% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 93.09% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.07 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.6 | ||
| Quick Ratio | 5.58 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-31.15%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y9.48%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)1104%
Revenue growth 3Y-63.12%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y